Targeting type 2 inflammation in bullous pemphigoid (BP): dupilumab as game changer opens new avenues.

Borradori, LucaLucaBorradoriHertl, MichaelMichaelHertl2024-12-302024-12-302024-12-06https://boris-portal.unibe.ch/handle/20.500.12422/194739en600 - Technology::610 - Medicine & healthTargeting type 2 inflammation in bullous pemphigoid (BP): dupilumab as game changer opens new avenues.article10.48620/787523965711910.1093/bjd/ljae465